Trial Outcomes & Findings for ZS Ph2/3 Dose-response Study in Japan (NCT NCT03127644)

NCT ID: NCT03127644

Last Updated: 2019-05-20

Results Overview

Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed at the Central Laboratory. Natural logarithm of S-K from 0 to 48 hours post dose are modelled by the random coefficients model including fixed effects of intercept, time, time x treatment and patient-level random effects for time and intercept. Exponential rate of change refers to the slope estimate from the random coefficients model.

Recruitment status

COMPLETED

Study phase

PHASE2/PHASE3

Target enrollment

103 participants

Primary outcome timeframe

From 0 to 48 hours.

Results posted on

2019-05-20

Participant Flow

Patients not receiving any therapy for hyperkalaemia and with 2 consecutive potassium values of ≥ 5.1 millimoles/litre (mmol/L) and ≤ 6.5 mmol/L (as measured by i-STAT, a portable blood analyser) were enrolled into 24 study sites in Japan from June 2017 to February 2018.

103 patients were randomised 1:1:1 to receive double-blind treatment of sodium zirconium cyclosilicate (ZS) 5 grams (g) three times daily (TID), ZS 10 g TID, or placebo TID for 48 hours.

Participant milestones

Participant milestones
Measure
ZS 5 g TID
ZS suspension was administered 5 g orally TID for 48 hours.
ZS 10 g TID
ZS suspension was administered 10 g orally TID for 48 hours.
Placebo TID
Placebo suspension was administered orally TID for 48 hours.
Overall Study
STARTED
34
36
33
Overall Study
COMPLETED
34
36
31
Overall Study
NOT COMPLETED
0
0
2

Reasons for withdrawal

Reasons for withdrawal
Measure
ZS 5 g TID
ZS suspension was administered 5 g orally TID for 48 hours.
ZS 10 g TID
ZS suspension was administered 10 g orally TID for 48 hours.
Placebo TID
Placebo suspension was administered orally TID for 48 hours.
Overall Study
Study-specific withdrawal criteria
0
0
2

Baseline Characteristics

ZS Ph2/3 Dose-response Study in Japan

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
ZS 5 g TID
n=34 Participants
ZS suspension was administered 5 g orally TID for 48 hours.
ZS 10 g TID
n=36 Participants
ZS suspension was administered 10 g orally TID for 48 hours.
Placebo TID
n=33 Participants
Placebo suspension was administered orally TID for 48 hours.
Total
n=103 Participants
Total of all reporting groups
Age, Continuous
72.4 Years
STANDARD_DEVIATION 7.9 • n=99 Participants
71.1 Years
STANDARD_DEVIATION 7.6 • n=107 Participants
76.1 Years
STANDARD_DEVIATION 6.8 • n=206 Participants
73.2 Years
STANDARD_DEVIATION 7.7 • n=7 Participants
Age, Customized
<55 years
0 Participants
n=99 Participants
1 Participants
n=107 Participants
0 Participants
n=206 Participants
1 Participants
n=7 Participants
Age, Customized
55 to 64 years
7 Participants
n=99 Participants
4 Participants
n=107 Participants
1 Participants
n=206 Participants
12 Participants
n=7 Participants
Age, Customized
≥65 years
27 Participants
n=99 Participants
31 Participants
n=107 Participants
32 Participants
n=206 Participants
90 Participants
n=7 Participants
Sex: Female, Male
Female
8 Participants
n=99 Participants
8 Participants
n=107 Participants
10 Participants
n=206 Participants
26 Participants
n=7 Participants
Sex: Female, Male
Male
26 Participants
n=99 Participants
28 Participants
n=107 Participants
23 Participants
n=206 Participants
77 Participants
n=7 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
34 Participants
n=99 Participants
36 Participants
n=107 Participants
33 Participants
n=206 Participants
103 Participants
n=7 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race (NIH/OMB)
Asian
34 Participants
n=99 Participants
36 Participants
n=107 Participants
33 Participants
n=206 Participants
103 Participants
n=7 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race (NIH/OMB)
White
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants

PRIMARY outcome

Timeframe: From 0 to 48 hours.

Population: The full analysis set included all patients randomised in the study.

Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed at the Central Laboratory. Natural logarithm of S-K from 0 to 48 hours post dose are modelled by the random coefficients model including fixed effects of intercept, time, time x treatment and patient-level random effects for time and intercept. Exponential rate of change refers to the slope estimate from the random coefficients model.

Outcome measures

Outcome measures
Measure
ZS 5 g TID
n=34 Participants
ZS suspension was administered 5 g orally TID for 48 hours.
ZS 10 g TID
n=36 Participants
ZS suspension was administered 10 g orally TID for 48 hours.
Placebo TID
n=33 Participants
Placebo suspension was administered orally TID for 48 hours.
Exponential Rate of Change in Serum Potassium (S-K) Values During the Initial 48 Hours of Study Drug Treatment
-0.00273 log (mmol/L) / hour
Standard Error 0.000276
-0.00508 log (mmol/L) / hour
Standard Error 0.000269
-0.00012 log (mmol/L) / hour
Standard Error 0.000288

SECONDARY outcome

Timeframe: At 48 hours.

Population: The full analysis set included all patients randomised in the study.

The percentage of patients who achieved normokalaemia (normalisation of S-K values to between 3.5 mmol/L and 5.0 mmol/L, inclusive) at 48 hours after start of dosing was determined. Patients with missing S-K values at 48 hours were regarded as not normokalaemic.

Outcome measures

Outcome measures
Measure
ZS 5 g TID
n=34 Participants
ZS suspension was administered 5 g orally TID for 48 hours.
ZS 10 g TID
n=36 Participants
ZS suspension was administered 10 g orally TID for 48 hours.
Placebo TID
n=33 Participants
Placebo suspension was administered orally TID for 48 hours.
Percentage of Patients Who Achieved Normokalaemia at 48 Hours
85.3 Percentage of Patients
91.7 Percentage of Patients
15.2 Percentage of Patients

SECONDARY outcome

Timeframe: From 0 to 24 hours.

Population: The full analysis set included all patients randomised in the study.

Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed at the Central Laboratory. Natural logarithm of S-K from 0 to 24 hours post dose are modelled by the random coefficients model including fixed effects of intercept, time, time x treatment and patient-level random effects for time and intercept. Exponential rate of change refers to the slope estimate from the random coefficients model.

Outcome measures

Outcome measures
Measure
ZS 5 g TID
n=34 Participants
ZS suspension was administered 5 g orally TID for 48 hours.
ZS 10 g TID
n=36 Participants
ZS suspension was administered 10 g orally TID for 48 hours.
Placebo TID
n=33 Participants
Placebo suspension was administered orally TID for 48 hours.
Exponential Rate of Change in S-K Values During the Initial 24 Hours of Study Drug Treatment
-0.00234 log (mmol/L) / hour
Standard Error 0.000468
-0.00403 log (mmol/L) / hour
Standard Error 0.000457
-0.00002 log (mmol/L) / hour
Standard Error 0.000489

SECONDARY outcome

Timeframe: At 24 hours.

Population: The full analysis set included all patients randomised in the study.

The percentage of patients who achieved normokalaemia (normalisation of S-K values to between 3.5 mmol/L and 5.0 mmol/L, inclusive) at 24 hours after start of dosing was determined. Patients with missing S-K values at 24 hours were regarded as not normokalaemic.

Outcome measures

Outcome measures
Measure
ZS 5 g TID
n=34 Participants
ZS suspension was administered 5 g orally TID for 48 hours.
ZS 10 g TID
n=36 Participants
ZS suspension was administered 10 g orally TID for 48 hours.
Placebo TID
n=33 Participants
Placebo suspension was administered orally TID for 48 hours.
Percentage of Patients Who Achieved Normokalaemia at 24 Hours
35.3 Percentage of Patients
83.3 Percentage of Patients
27.3 Percentage of Patients

SECONDARY outcome

Timeframe: From baseline to end of study (9 days).

Population: The full analysis set included all patients randomised in the study.

The percentage of patients who achieved normokalaemia (normalisation of S-K values to between 3.5 mmol/L and 5.0 mmol/L, inclusive) at each each scheduled potassium assessment time point after the start of dosing was determined. Patients with missing S-K values were regarded as not normokalaemic.

Outcome measures

Outcome measures
Measure
ZS 5 g TID
n=34 Participants
ZS suspension was administered 5 g orally TID for 48 hours.
ZS 10 g TID
n=36 Participants
ZS suspension was administered 10 g orally TID for 48 hours.
Placebo TID
n=33 Participants
Placebo suspension was administered orally TID for 48 hours.
Percentage of Patients Who Achieved Normokalaemia at Each Scheduled Potassium Assessment Time Point
Baseline
2.9 Percentage of Patients
5.6 Percentage of Patients
0.0 Percentage of Patients
Percentage of Patients Who Achieved Normokalaemia at Each Scheduled Potassium Assessment Time Point
1 hour after first dose
29.4 Percentage of Patients
47.2 Percentage of Patients
21.2 Percentage of Patients
Percentage of Patients Who Achieved Normokalaemia at Each Scheduled Potassium Assessment Time Point
2 hours after first dose
41.2 Percentage of Patients
58.3 Percentage of Patients
42.4 Percentage of Patients
Percentage of Patients Who Achieved Normokalaemia at Each Scheduled Potassium Assessment Time Point
4 hours after first dose
44.1 Percentage of Patients
63.9 Percentage of Patients
42.4 Percentage of Patients
Percentage of Patients Who Achieved Normokalaemia at Each Scheduled Potassium Assessment Time Point
24 hours after first dose
35.3 Percentage of Patients
83.3 Percentage of Patients
27.3 Percentage of Patients
Percentage of Patients Who Achieved Normokalaemia at Each Scheduled Potassium Assessment Time Point
25 hours after first dose
73.5 Percentage of Patients
97.2 Percentage of Patients
18.2 Percentage of Patients
Percentage of Patients Who Achieved Normokalaemia at Each Scheduled Potassium Assessment Time Point
28 hours after first dose
67.6 Percentage of Patients
97.2 Percentage of Patients
36.4 Percentage of Patients
Percentage of Patients Who Achieved Normokalaemia at Each Scheduled Potassium Assessment Time Point
48 hours after first dose
85.3 Percentage of Patients
91.7 Percentage of Patients
15.2 Percentage of Patients
Percentage of Patients Who Achieved Normokalaemia at Each Scheduled Potassium Assessment Time Point
End of study (Last dose + 7 days)
55.9 Percentage of Patients
61.1 Percentage of Patients
27.3 Percentage of Patients

SECONDARY outcome

Timeframe: From baseline to end of study (9 days).

Population: The full analysis set included all patients randomised in the study.

Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed locally using i-STAT devices, and at the Central Laboratory. S-K values measured at each time point and end of study visit were recorded and mean change from baseline is displayed.

Outcome measures

Outcome measures
Measure
ZS 5 g TID
n=34 Participants
ZS suspension was administered 5 g orally TID for 48 hours.
ZS 10 g TID
n=36 Participants
ZS suspension was administered 10 g orally TID for 48 hours.
Placebo TID
n=33 Participants
Placebo suspension was administered orally TID for 48 hours.
Mean Change From Baseline in S-K Values at All Measured Time Intervals
1 hour after first dose
-0.20 mmol/L
Standard Deviation 0.34
-0.37 mmol/L
Standard Deviation 0.35
-0.13 mmol/L
Standard Deviation 0.32
Mean Change From Baseline in S-K Values at All Measured Time Intervals
2 hours after first dose
-0.41 mmol/L
Standard Deviation 0.28
-0.50 mmol/L
Standard Deviation 0.40
-0.33 mmol/L
Standard Deviation 0.30
Mean Change From Baseline in S-K Values at All Measured Time Intervals
4 hours after first dose
-0.40 mmol/L
Standard Deviation 0.32
-0.53 mmol/L
Standard Deviation 0.36
-0.43 mmol/L
Standard Deviation 0.31
Mean Change From Baseline in S-K Values at All Measured Time Intervals
24 hours after first dose
-0.51 mmol/L
Standard Deviation 0.30
-0.69 mmol/L
Standard Deviation 0.38
-0.22 mmol/L
Standard Deviation 0.35
Mean Change From Baseline in S-K Values at All Measured Time Intervals
25 hours after first dose
-0.74 mmol/L
Standard Deviation 0.31
-1.00 mmol/L
Standard Deviation 0.45
-0.27 mmol/L
Standard Deviation 0.31
Mean Change From Baseline in S-K Values at All Measured Time Intervals
28 hours after first dose
-0.72 mmol/L
Standard Deviation 0.35
-1.12 mmol/L
Standard Deviation 0.39
-0.41 mmol/L
Standard Deviation 0.43
Mean Change From Baseline in S-K Values at All Measured Time Intervals
48 hours after first dose
-0.83 mmol/L
Standard Deviation 0.31
-1.30 mmol/L
Standard Deviation 0.48
-0.24 mmol/L
Standard Deviation 0.34
Mean Change From Baseline in S-K Values at All Measured Time Intervals
End of study (Last dose + 7 days)
-0.56 mmol/L
Standard Deviation 0.38
-0.66 mmol/L
Standard Deviation 0.52
-0.20 mmol/L
Standard Deviation 0.59

SECONDARY outcome

Timeframe: From baseline to end of study (9 days).

Population: The full analysis set included all patients randomised in the study.

Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed locally using i-STAT devices, and at the Central Laboratory. S-K values measured at each time point and end of study visit were recorded and mean percent change from baseline is displayed.

Outcome measures

Outcome measures
Measure
ZS 5 g TID
n=34 Participants
ZS suspension was administered 5 g orally TID for 48 hours.
ZS 10 g TID
n=36 Participants
ZS suspension was administered 10 g orally TID for 48 hours.
Placebo TID
n=33 Participants
Placebo suspension was administered orally TID for 48 hours.
Mean Percent Change From Baseline in S-K Values at All Measured Time Intervals
1 hour after first dose
-3.61 Percent change
Standard Deviation 6.28
-6.72 Percent change
Standard Deviation 6.29
-2.32 Percent change
Standard Deviation 5.60
Mean Percent Change From Baseline in S-K Values at All Measured Time Intervals
2 hours after first dose
-7.46 Percent change
Standard Deviation 5.04
-9.07 Percent change
Standard Deviation 6.88
-6.06 Percent change
Standard Deviation 5.40
Mean Percent Change From Baseline in S-K Values at All Measured Time Intervals
4 hours after first dose
-7.08 Percent change
Standard Deviation 5.65
-9.70 Percent change
Standard Deviation 6.53
-7.77 Percent change
Standard Deviation 5.62
Mean Percent Change From Baseline in S-K Values at All Measured Time Intervals
24 hours after first dose
-8.98 Percent change
Standard Deviation 5.33
-12.51 Percent change
Standard Deviation 6.30
-3.81 Percent change
Standard Deviation 6.24
Mean Percent Change From Baseline in S-K Values at All Measured Time Intervals
25 hours after first dose
-13.20 Percent change
Standard Deviation 5.42
-18.06 Percent change
Standard Deviation 7.05
-4.77 Percent change
Standard Deviation 5.66
Mean Percent Change From Baseline in S-K Values at All Measured Time Intervals
28 hours after first dose
-12.90 Percent change
Standard Deviation 6.10
-20.47 Percent change
Standard Deviation 6.38
-7.21 Percent change
Standard Deviation 7.61
Mean Percent Change From Baseline in S-K Values at All Measured Time Intervals
48 hours after first dose
-14.81 Percent change
Standard Deviation 5.08
-23.64 Percent change
Standard Deviation 8.27
-4.06 Percent change
Standard Deviation 5.93
Mean Percent Change From Baseline in S-K Values at All Measured Time Intervals
End of study (Last dose + 7 days)
-9.85 Percent change
Standard Deviation 6.51
-11.89 Percent change
Standard Deviation 9.07
-3.15 Percent change
Standard Deviation 9.99

SECONDARY outcome

Timeframe: From 0 to 48 hours.

Population: The full analysis set included all patients randomised in the study.

The distribution of time to normalisation of S-K values (defined as S-K values between 3.5 mmol/L and 5.0 mmol/L, inclusive) was measured. A patient who reached at least one S-K within normal range was counted as an event regardless of S-K value after that time point. Patients who did not achieve normokalaemia within 48 hours were censored.

Outcome measures

Outcome measures
Measure
ZS 5 g TID
n=34 Participants
ZS suspension was administered 5 g orally TID for 48 hours.
ZS 10 g TID
n=36 Participants
ZS suspension was administered 10 g orally TID for 48 hours.
Placebo TID
n=33 Participants
Placebo suspension was administered orally TID for 48 hours.
Time to Normalisation in S-K Values
3.883 Hours
Interval 1.767 to 23.083
1.758 Hours
Interval 1.0 to 3.967
3.867 Hours
Interval 1.917 to
Upper limit not reached.

SECONDARY outcome

Timeframe: From 0 to 48 hours.

Population: The full analysis set included all patients randomised in the study.

The median time (hours) for S-K values to decrease by 0.5 mmol/L was measured.

Outcome measures

Outcome measures
Measure
ZS 5 g TID
n=34 Participants
ZS suspension was administered 5 g orally TID for 48 hours.
ZS 10 g TID
n=36 Participants
ZS suspension was administered 10 g orally TID for 48 hours.
Placebo TID
n=33 Participants
Placebo suspension was administered orally TID for 48 hours.
Time to a Decrease in S-K Levels of 0.5 mmol/L
3.883 Hours
Interval 1.933 to 19.767
2.892 Hours
Interval 1.083 to 4.1
4.050 Hours
Interval 1.983 to 23.667

Adverse Events

ZS 5 g TID

Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths

ZS 10 g TID

Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths

Placebo TID

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
ZS 5 g TID
n=34 participants at risk
ZS suspension was administered 5 g orally TID for 48 hours.
ZS 10 g TID
n=36 participants at risk
ZS suspension was administered 10 g orally TID for 48 hours.
Placebo TID
n=33 participants at risk
Placebo suspension was administered orally TID for 48 hours.
Infections and infestations
Respiratory tract infection
0.00%
0/34 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
0.00%
0/36 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
3.0%
1/33 • Number of events 1 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
Infections and infestations
Viral upper respiratory tract infection
2.9%
1/34 • Number of events 1 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
0.00%
0/36 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
0.00%
0/33 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
Blood and lymphatic system disorders
Nephrogenic anaemia
2.9%
1/34 • Number of events 1 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
0.00%
0/36 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
0.00%
0/33 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
Metabolism and nutrition disorders
Hypoglycaemia
0.00%
0/34 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
2.8%
1/36 • Number of events 1 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
0.00%
0/33 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
Nervous system disorders
Tension headache
0.00%
0/34 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
2.8%
1/36 • Number of events 1 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
0.00%
0/33 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
Nervous system disorders
Tremor
0.00%
0/34 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
2.8%
1/36 • Number of events 5 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
0.00%
0/33 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
Cardiac disorders
Ventricular extrasystoles
0.00%
0/34 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
2.8%
1/36 • Number of events 1 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
0.00%
0/33 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
Gastrointestinal disorders
Constipation
2.9%
1/34 • Number of events 1 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
0.00%
0/36 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
0.00%
0/33 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
Skin and subcutaneous tissue disorders
Erythema
0.00%
0/34 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
2.8%
1/36 • Number of events 1 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
0.00%
0/33 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
General disorders
Thirst
2.9%
1/34 • Number of events 1 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
0.00%
0/36 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.
0.00%
0/33 • Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.

Additional Information

Global Clinical Lead

AstraZeneca

Phone: +1 302 885 1180

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place